Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 603035 | ISIN: US0042251084 | Ticker-Symbol: DR6
Tradegate
13.05.25 | 07:30
15,845 Euro
+3,12 % +0,480
1-Jahres-Chart
ACADIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACADIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
15,18015,40513:59
15,17015,39514:01

Aktuelle News zur ACADIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAcadia Pharmaceuticals files to sell 43.58M shares of common stock for holders1
07.05.ACADIA PHARMACEUTICALS INC - 8-K, Current Report3
07.05.Acadia Pharma GAAP EPS of $0.11 beats by $0.02, revenue of $244.3M beats by $5.33M8
16.04.ACADIA PHARMACEUTICALS INC - 8-K, Current Report2
14.03.Acadia Pharmaceuticals issues new employee stock awards3
04.03.Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)3
03.03.Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study310Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study...
► Artikel lesen
ACADIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.02.ACADIA PHARMACEUTICALS INC - 10-K, Annual Report-
27.02.Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews1
27.02.Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth1
26.02.Acadia Pharma GAAP EPS of $0.86 beats by $0.63, revenue of $259.6M misses by $13.44M5
26.02.ACADIA PHARMACEUTICALS INC - 8-K, Current Report-
15.01.Acadia submits MAA to EMA for Rett syndrome therapy2
14.01.Acadia Pharma Submits MAA To EU Agency For Approval Of Trofinetide In Rett Syndrome-
14.01.Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome278-- Filing marks company's first Marketing Authorization Application in Europe Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization...
► Artikel lesen
02.01.Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing4
31.12.24Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday5
31.12.24Acadia Pharmaceuticals will replace Independent Bank Group in S&P SmallCap 6006
30.12.24S&P Dow Jones Indices: Acadia Pharmaceuticals Set to Join S&P SmallCap 600233NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600...
► Artikel lesen
11.12.24ACADIA PHARMACEUTICALS INC - 8-K, Current Report-
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2